Systematic Hereditary Pancreatic Cancer Risk Assessment and Implications for Personalized Therapy
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03060720|
Recruitment Status : Recruiting
First Posted : February 23, 2017
Last Update Posted : February 7, 2019
|Condition or disease|
This research is being done to identify which pancreatic cancer patients should undergo genetic evaluation. A patient's personal and family history of cancer is the information typically used to make this decision, but there are currently no accurate, evidence-based guidelines that exist to help doctors use this information to make a decision.
The investigators hope that by testing all new pancreatic cancer patients, they can determine which clinical factors predict for genetic mutations in order to create a risk assessment tool.
The investigators want to determine which patients with pancreatic cancer will benefit from genetic testing. To do so, the investigators will offer all patients with pancreatic cancer in the Dana-Farber Gastrointestinal Oncology clinic referral for genetic evaluation. At the Cancer Genetics and Prevention clinic appointment, the provider will review the patient's personal and familial history of cancer and offer genetic testing.
|Study Type :||Observational|
|Estimated Enrollment :||375 participants|
|Official Title:||Systematic Hereditary Pancreatic Cancer Risk Assessment and Implications for Personalized Therapy|
|Actual Study Start Date :||February 24, 2017|
|Estimated Primary Completion Date :||February 2020|
|Estimated Study Completion Date :||February 2022|
- We will measure clinical factors (e.g. # of PDAC patients with a personal history of x,y,z; # of PDAC patients with a family history of x,y,z; # PDAC patients with a germline mutation in x,y,z) so as to develop a risk assessment tool [ Time Frame: Up to 5 years ]
- Evaluate Patient Experience With Genetic Testing [ Time Frame: up to 5 years ]
- Summarize patient satisfaction with Genetic counseling [ Time Frame: up to 5 years ]
- Number of patients who disclose genetic testing results to relatives [ Time Frame: up to 5 years ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03060720
|Contact: Matthew B Yurgelun, MDfirstname.lastname@example.org|
|Contact: Chinedu Ukaegbuemail@example.com|
|United States, Massachusetts|
|Dana Farber Cancer Institute||Recruiting|
|Boston, Massachusetts, United States, 02215|
|Contact: Matthew B Yurgelun, MD 617-632-6835|
|Principal Investigator: Matthew B Yurgelun, MD|
|Principal Investigator:||Matthew B Yurgelun, MD||Dana-Farber Cancer Institute|